Home › Funds › Blue Owl Capital Holdings LP › AKTS
Blue Owl Capital Holdings LP position in AKTS
AKTIS ONCOLOGY INC · Health Care
Blue Owl Capital Holdings LP reported holding 3,343,827 shares of AKTS (AKTIS ONCOLOGY INC) in its Q3 2026 13F filing — a position valued at US$65.1M, representing 12.24% of its reported portfolio and ranking #2 among its reported holdings. Blue Owl Capital Holdings LP has disclosed AKTS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Blue Owl Capital Holdings LP's AKTS position evolved
Blue Owl Capital Holdings LP first disclosed a stake in AKTS in Q1 2026 at 3,161,348 shares (US$56.6M). The position peaked in Q2 2026 at 3,070,219 shares, worth US$99.0M. Across 3 filings, Blue Owl Capital Holdings LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,343,827 shares valued at US$65.1M — an increase of 273,608 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 3.16M | $56.56M | New |
| Q2 2026 | 3.07M | $98.95M | Reduce |
| Q3 2026 | 3.34M | $65.10M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AKTS and 13F data
AKTS (AKTIS ONCOLOGY INC) is a Health Care company. 123 other funds we track also report a position in AKTS — the largest reported positions include MPM BioImpact LLC (US$155.9M), EcoR1 Capital, LLC (US$155.5M), RTW INVESTMENTS, LP (US$51.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AKTS
- MPM BioImpact LLC 4.84M sh · $155.86M · Q2 2026
- EcoR1 Capital, LLC 4.82M sh · $155.49M · Q2 2026
- RTW INVESTMENTS, LP 1.59M sh · $51.31M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.31M sh · $42.36M · Q2 2026
- BAKER BROS. ADVISORS LP 996.35K sh · $32.11M · Q2 2026
- Octagon Capital Advisors LP 960.85K sh · $30.97M · Q2 2026
- Merck & Co., Inc. 952.84K sh · $30.71M · Q2 2026
- TCG Crossover Management, LLC 696.56K sh · $22.45M · Q2 2026
- Avidity Partners Management LP 484.20K sh · $15.61M · Q2 2026
- a16z Capital Management, L.L.C. 415.00K sh · $13.38M · Q2 2026
More on Blue Owl Capital Holdings LP
FAQ
How long has Blue Owl Capital Holdings LP held AKTS?
Blue Owl Capital Holdings LP has disclosed AKTS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Blue Owl Capital Holdings LP's current position in AKTS?
As of Q3 2026, Blue Owl Capital Holdings LP holds 3.34M shares of AKTS (AKTIS ONCOLOGY INC), valued at $65.10M, representing 12.24% of its reported portfolio and ranking #2.
Has Blue Owl Capital Holdings LP been buying or selling AKTS?
In the latest 13F filing (Q3 2026), Blue Owl Capital Holdings LP increased its position in AKTS. The position peaked in Q2 2026 at 3.07M shares.
Which other funds hold AKTS?
Other major institutional holders of AKTS include MPM BioImpact LLC, EcoR1 Capital, LLC, RTW INVESTMENTS, LP, among 123 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.